K Krüger1. 1. Rheumatologisches Praxiszentrum, St. Bonifatius Str. 5, 81541, München, Deutschland. Klaus.krueger@med.uni-muenchen.de.
Abstract
BACKGROUND: Rheumatoid arthritis (RA), psoriatic arthritis and axial spondyloarthritis are severe diseases, which without adequate treatment lead to extremely reduced mobility, functional status and quality of life. OBJECTIVE: The effects of biologics and further new antirheumatic drugs on the burden of disease. METHODS: Evaluation of study results and register data dealing with the efficacy and safety of these drugs. RESULTS: Biologics have been proven to dramatically improve the outcome of all three diseases and contributed to the fact that remission is a realistic target today. In addition, the cardiovascular risk and mortality in RA have been reduced and structural damage is considerably blocked by biologics. Recently Janus kinase (JAK) inhibitors contributed to the treatment possibilities in the same way. Biologics as well as JAK inhibitors offer an excellent safety profile and tolerability with infections being the most important risk. CONCLUSION: With the availability of biologics and additional new drugs all three diseases have lost the status of difficult to treat diseases. Their usage according to the guidelines ensures that the burden of disease can been minimalized in most cases. The benefit-risk profile of these drugs has been shown to be excellent.
BACKGROUND:Rheumatoid arthritis (RA), psoriatic arthritis and axial spondyloarthritis are severe diseases, which without adequate treatment lead to extremely reduced mobility, functional status and quality of life. OBJECTIVE: The effects of biologics and further new antirheumatic drugs on the burden of disease. METHODS: Evaluation of study results and register data dealing with the efficacy and safety of these drugs. RESULTS: Biologics have been proven to dramatically improve the outcome of all three diseases and contributed to the fact that remission is a realistic target today. In addition, the cardiovascular risk and mortality in RA have been reduced and structural damage is considerably blocked by biologics. Recently Janus kinase (JAK) inhibitors contributed to the treatment possibilities in the same way. Biologics as well as JAK inhibitors offer an excellent safety profile and tolerability with infections being the most important risk. CONCLUSION: With the availability of biologics and additional new drugs all three diseases have lost the status of difficult to treat diseases. Their usage according to the guidelines ensures that the burden of disease can been minimalized in most cases. The benefit-risk profile of these drugs has been shown to be excellent.
Authors: Désirée van der Heijde; Sofia Ramiro; Robert Landewé; Xenofon Baraliakos; Filip Van den Bosch; Alexandre Sepriano; Andrea Regel; Adrian Ciurea; Hanne Dagfinrud; Maxime Dougados; Floris van Gaalen; Pál Géher; Irene van der Horst-Bruinsma; Robert D Inman; Merryn Jongkees; Uta Kiltz; Tore K Kvien; Pedro M Machado; Helena Marzo-Ortega; Anna Molto; Victoria Navarro-Compàn; Salih Ozgocmen; Fernando M Pimentel-Santos; John Reveille; Martin Rudwaleit; Jochen Sieper; Percival Sampaio-Barros; Dieter Wiek; Jürgen Braun Journal: Ann Rheum Dis Date: 2017-01-13 Impact factor: 19.103
Authors: Jasvinder A Singh; Chris Cameron; Shahrzad Noorbaloochi; Tyler Cullis; Matthew Tucker; Robin Christensen; Elizabeth Tanjong Ghogomu; Doug Coyle; Tammy Clifford; Peter Tugwell; George A Wells Journal: Lancet Date: 2015-05-11 Impact factor: 79.321
Authors: Philip J Mease; Désirée van der Heijde; Christopher T Ritchlin; Masato Okada; Raquel S Cuchacovich; Catherine L Shuler; Chen-Yen Lin; Daniel K Braun; Chin H Lee; Dafna D Gladman Journal: Ann Rheum Dis Date: 2016-08-23 Impact factor: 19.103
Authors: Gerd R Burmester; Yong Lin; Rahul Patel; Janet van Adelsberg; Erin K Mangan; Neil M H Graham; Hubert van Hoogstraten; Deborah Bauer; Juan Ignacio Vargas; Eun Bong Lee Journal: Ann Rheum Dis Date: 2016-11-17 Impact factor: 19.103
Authors: A Strangfeld; A Richter; B Siegmund; P Herzer; K Rockwitz; W Demary; M Aringer; Y Meißner; A Zink; J Listing Journal: Ann Rheum Dis Date: 2016-07-12 Impact factor: 19.103
Authors: Roy Fleischmann; Michael Schiff; Désirée van der Heijde; Cesar Ramos-Remus; Alberto Spindler; Marina Stanislav; Cristiano A F Zerbini; Sirel Gurbuz; Christina Dickson; Stephanie de Bono; Douglas Schlichting; Scott Beattie; Wen-Ling Kuo; Terence Rooney; William Macias; Tsutomu Takeuchi Journal: Arthritis Rheumatol Date: 2017-03 Impact factor: 10.995